Depression | I & C | Invest in Quality. Contribute to Society.


ProductStrengthPack Size
Duloxetine Gastro-Resistant Capsules30mg28 capsules / box
Duloxetine Gastro-Resistant Capsules60mg28 capsules / box
Escitalopram Tablets10mg28 tablets / box
Escitalopram Tablets20mg28 tablets / box
Quetiapine Extended-Release Tablets50mg60 tablets / box
Quetiapine Extended-Release Tablets200mg60 tablets / box
Quetiapine Extended-Release Tablets300mg60 tablets / box
Quetiapine Extended-Release Tablets400mg60 tablets / box
Venlafaxine Prolonged-Release Capsules (Deprevix)37.5mg28 capsules / box
Venlafaxine Prolonged-Release Capsules (Deprevix)75mg28 capsules / box
Venlafaxine Prolonged-Release Capsules (Deprevix)150mg28 capsules / box
* The above product list shows our products which are approved by Hong Kong Department of Health only. It does not mean that all products are already placed in the market. For any product or business enquiries please contact us at or (852) 2891 0581 for further details.


Depression is a common psychological disorder affecting over 250 million people worldwide. Patients usually present symptoms such as depressed mood, decreased pleasure, loss of appetite and sleeping problems. Besides psychotherapy, depression can be treated with antidepressants. However, clinical improvement may take a few weeks to occur. Patients should be closely monitored for any increased suicidal risk until such improvement occurs. Antidepressants should be discontinued gradually to reduce the risk of withdrawal symptoms.

Selective Serotonin Reuptake Inhibitors (SSRIs)
SSRIs are the first-line treatment option for depression. They are better tolerated than older antidepressants such as TCAs and MAOIs. Escitalopram is an S-enantiomer of citalopram, one of the first marketed SSRI, and is more effective in achieving acute response and remission rate than citalopram.

Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)
SNRIs are the preferred treatment option when SSRIs are not effective or tolerated. Venlafaxine has been found to significantly decreases the severity of depression more than SSRIs, suggesting that it may be marginally more effective than SSRIs.

Several antipsychotics also exert antidepressant activity, possibly as a 5-HT1A partial agonist. Extended-release Quetiapine is indicated for the treatment of recurrent depression.